JP2009512676A5 - - Google Patents

Download PDF

Info

Publication number
JP2009512676A5
JP2009512676A5 JP2008536146A JP2008536146A JP2009512676A5 JP 2009512676 A5 JP2009512676 A5 JP 2009512676A5 JP 2008536146 A JP2008536146 A JP 2008536146A JP 2008536146 A JP2008536146 A JP 2008536146A JP 2009512676 A5 JP2009512676 A5 JP 2009512676A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
hydrogen
halogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008536146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/002930 external-priority patent/WO2007045979A1/en
Publication of JP2009512676A publication Critical patent/JP2009512676A/ja
Publication of JP2009512676A5 publication Critical patent/JP2009512676A5/ja
Withdrawn legal-status Critical Current

Links

JP2008536146A 2005-10-19 2006-10-19 ムスカリン性受容体アンタゴニストの医薬組成物 Withdrawn JP2009512676A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2794DE2005 2005-10-19
PCT/IB2006/002930 WO2007045979A1 (en) 2005-10-19 2006-10-19 Pharmaceutical compositions of muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
JP2009512676A JP2009512676A (ja) 2009-03-26
JP2009512676A5 true JP2009512676A5 (cg-RX-API-DMAC7.html) 2009-12-03

Family

ID=37527068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536146A Withdrawn JP2009512676A (ja) 2005-10-19 2006-10-19 ムスカリン性受容体アンタゴニストの医薬組成物

Country Status (8)

Country Link
US (1) US20090221664A1 (cg-RX-API-DMAC7.html)
EP (1) EP1948164A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009512676A (cg-RX-API-DMAC7.html)
AU (1) AU2006305619A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0617674A2 (cg-RX-API-DMAC7.html)
CA (1) CA2626612A1 (cg-RX-API-DMAC7.html)
RU (1) RU2008119323A (cg-RX-API-DMAC7.html)
WO (1) WO2007045979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
EP2059505A2 (en) * 2006-09-04 2009-05-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
US20100152269A1 (en) * 2006-12-21 2010-06-17 Ranbaxy Laboratories Limited Modified-release formulations of azabicyclo derivatives
EP2111861A1 (en) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (zh) * 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598621A (en) 1898-02-08 Refrigerating apparatus
US605344A (en) 1898-06-07 sabin
US630517A (en) 1899-04-05 1899-08-08 Edward L Perry Composition for printers' inking-rollers.
NL124473C (cg-RX-API-DMAC7.html) 1960-07-26
GB1047518A (en) 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
NL128816C (cg-RX-API-DMAC7.html) 1965-04-22
GB1158492A (en) 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3639434A (en) 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
US3780177A (en) 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
CH540244A (de) 1967-11-17 1973-08-15 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
GB1253831A (en) 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3700681A (en) 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3947478A (en) 1972-01-12 1976-03-30 Akzona Incorporated Alkylated 3,20-diketo-Δ4 -steroids of the pregnane series
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (cg-RX-API-DMAC7.html) 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
SE378110B (cg-RX-API-DMAC7.html) 1972-05-19 1975-08-18 Bofors Ab
FR2231374B1 (cg-RX-API-DMAC7.html) 1973-05-30 1976-10-22 Jouveinal Sa
US4098804A (en) 1973-05-30 1978-07-04 Jouveinal S.A. Esters of 21-thiol prednisone and prednisolone
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
ZA744259B (en) 1973-08-17 1975-06-25 American Cyanamid Co Topical steroid
US3980778A (en) 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4076708A (en) 1976-12-22 1978-02-28 Schering Corporation Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby
US4124707A (en) 1976-12-22 1978-11-07 Schering Corporation 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
US4081541A (en) 1976-12-28 1978-03-28 Rorer Italiana S.P.A. Steroid derivatives
DE2735110A1 (de) 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
JPS6040439B2 (ja) 1978-03-29 1985-09-11 大正製薬株式会社 ヒドロコルチゾン誘導体
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
DE3163871D1 (en) 1980-07-09 1984-07-05 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates
US4298604B1 (en) 1980-10-06 1998-12-22 Schering Corp Clotrimazole-betamethasone dipropionate combination
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3133081A1 (de) 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung
US4472392A (en) 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
CA1326662C (en) 1988-03-09 1994-02-01 Yutaka Mizushima 11.beta.,17.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(e,e)-3,7,11-trimethyl-2,6,10-dodecatrienoate]
US5278156A (en) 1988-03-09 1994-01-11 Kuraray Co., Ltd. 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate]
US5001160A (en) 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5281601A (en) 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
HU213401B (en) 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
DZ1966A1 (fr) 1995-02-06 2002-10-15 Astra Ab Combinaison pharmaceutique nouvelle.
US5750540A (en) 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
ES2172583T3 (es) 1995-06-06 2002-10-01 Pfizer 5,6-dihidro-9h-pirazol(3,4-c)-1,2,4-triazol(4,3-alfa)piridinas triciclicas.
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AU2793197A (en) 1996-05-31 1998-01-05 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
PL189641B1 (pl) 1996-11-11 2005-09-30 Altana Pharma Ag Benzonaftyrydyny, środki farmaceutyczne je zawierające oraz zastosowanie benzonaftyrydyn
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
PL198983B1 (pl) 1998-04-28 2008-08-29 Elbion Ag Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania
ITMI981670A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
GB9824160D0 (en) 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
IL152701A0 (en) 2000-05-25 2003-06-24 Hoffmann La Roche Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
US20030199494A1 (en) 2000-06-14 2003-10-23 Paul Evans 1,2,3,5-tetrahydrobenzo'c!azepin-4-one derivatives having muscarinic antagonist activity
KR100751981B1 (ko) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE60121813T2 (de) 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
AU2002345266B2 (en) * 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
JP2006522787A (ja) * 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
EP1713471B1 (en) * 2004-02-06 2012-01-18 MEDA Pharma GmbH & Co. KG Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
WO2006003587A2 (en) * 2004-07-01 2006-01-12 Ranbaxy Laboratories Limited Solid oral dosage forms of azabicyclo derivatives
EP1828126A1 (en) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
WO2006117754A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv

Similar Documents

Publication Publication Date Title
JP2009512676A5 (cg-RX-API-DMAC7.html)
JP2007502807A5 (cg-RX-API-DMAC7.html)
JP2015516000A5 (cg-RX-API-DMAC7.html)
AR083842A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis
AU2008212039A1 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brian, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease
JP2010509356A5 (cg-RX-API-DMAC7.html)
JP2014514360A5 (cg-RX-API-DMAC7.html)
JP2011515483A5 (cg-RX-API-DMAC7.html)
JP2010513434A5 (cg-RX-API-DMAC7.html)
WO2005051946A3 (en) Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2009082268A3 (ru) ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
JP2006500394A5 (cg-RX-API-DMAC7.html)
RU2004126613A (ru) Замещенные индолы в качестве агонистов альфа-1
JP2010155827A5 (cg-RX-API-DMAC7.html)
NZ601077A (en) Use of an adrenal hormone-modifying agent
RU2011125314A (ru) Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
JP2007520440A5 (cg-RX-API-DMAC7.html)
MX2012002534A (es) Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato.
JP2023552610A5 (cg-RX-API-DMAC7.html)
JP2021528446A5 (cg-RX-API-DMAC7.html)
EA201270602A1 (ru) N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
JP2012507525A5 (cg-RX-API-DMAC7.html)
CA2619897A1 (fr) Nouveaux derives tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2010509334A5 (cg-RX-API-DMAC7.html)